ABIVAX SA (ABVX.PA) Stock Price, Forecast & Analysis
Europe • Euronext Paris • EPA:ABVX • FR0012333284
ABVX.PA Key Statistics, Chart & Performance
The current stock price of ABVX.PA is 94.8 EUR. In the past month the price decreased by -17.57%. In the past year, price increased by 1469.54%.
ABVX.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ABVX.PA. When comparing the yearly performance of all stocks, ABVX.PA is one of the better performing stocks in the market, outperforming 99.7% of all stocks.
ABVX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVX.PA. ABVX.PA may be in some trouble as it scores bad on both profitability and health.
ABVX.PA Financial Highlights
Over the last trailing twelve months ABVX.PA reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX.PA Forecast & Estimates
14 analysts have analysed ABVX.PA and the average price target is 118.58 EUR. This implies a price increase of 25.08% is expected in the next year compared to the current price of 94.8.
For the next year, analysts expect an EPS growth of -20.7% and a revenue growth 91.53% for ABVX.PA
ABVX.PA Ownership
About ABVX.PA
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA / ABVX.PA FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the stock price of ABIVAX SA today?
The current stock price of ABVX.PA is 94.8 EUR. The price decreased by -1.15% in the last trading session.
Does ABIVAX SA pay dividends?
ABVX.PA does not pay a dividend.
How is the ChartMill rating for ABIVAX SA?
ABVX.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ABVX stock?
ABVX.PA stock is listed on the Euronext Paris exchange.
Is ABIVAX SA (ABVX.PA) expected to grow?
The Revenue of ABIVAX SA (ABVX.PA) is expected to grow by 91.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does ABIVAX SA (ABVX.PA) report earnings?
ABIVAX SA (ABVX.PA) will report earnings on 2026-03-23, after the market close.